MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026

MiNK Therapeutics, Inc.

Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.
Phase 2 trial for agenT-797 in ARDS/hypoxemic pneumonia to initiate 1H 2026; early data by year end.
GVHD program funded by NIH STTR grant and Mary Gooze award; trial launch May 2026, preliminary data 2H 2026.
C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-TCR iNKT in pediatric oncology.
Appointments: Dr. Terese Hammond as Head of Pulmonary; Melissa Orilall as Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.

Period: the fourth quarter and full year ended December 31, 2025
Net income: net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share
Result: reported results

Exact text from the filing

On March 31, 2026, MiNK Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-133346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.